



Talk to QPS

QPS is Your Global Link to all Your
Translational Medicine Sourcing
Needs



Introduction of QPS' Translational Medicine Services:

With three highly specialized laboratory sites established in the USA, Netherlands and Taiwan, where QPS' translational medicine laboratory scientists routinely develop and validate over 50 biomarker methods annually, QPS has positioned itself as a true global player in translational medicine laboratory services. As an experienced provider of genotyping and pharmacogenomics services for clinical trials, QPS offers pharmacogenetic solutions to help guide drug development teams at various levels, including patient stratification, toxicity prediction, evaluation of PK profiles, dose determination, and treatment decisions.

Why should QPS be your first and only choice to conduct all of your TLM studies?

Direct Peer-to-Peer Interactions

At QPS we realize that the quality of the biomarker data you receive from us is directly related to the scientific expertise that is available within our laboratories. Each of your biomarker programs will have a dedicated Study Director assigned who has the overall responsibility for the conduct of your study and is your single point of study control to get your science done. The Study Director is available to answer all your questions and provide analysis and interpretation of biomarker data.

Fast Turnaround

The direction taken by your drug discovery and development programs can be substantially influenced by the timely availability of biomarker data. QPS' state-of-the-art specialized biomarker laboratory services and fast turn around times will help you make your "go/no-go" decisions faster while reducing your total preclinical and clinical study costs. To meet your timeline requirements, we offer for instance custom genotyping services with 48-72 hour data turnaround for patient stratification and inclusion/exclusion decisions to support your global clinical Phase I, II, III, and IV trials.

Global Flexibility

Benefit from QPS' global resources with the flexibility to transfer methods among any of our three specialized laboratory sites in the USA, Netherlands, and Taiwan. QPS can provide you with a truly "fit-for-purpose" option to support your global clinical studies. With its worldwide laboratory capabilities, QPS is in an excellent position to cater to the growing global biomarker needs of pharmaceutical and biotech companies by providing access to a large biomarker menu for many types of therapeutic indications.

Customer Focus

QPS focuses on the needs of each client and works to ensure that those needs are met. We strive to ensure optimal communications so you have always complete visibility into your project's status and can rest assured that your deadlines will be met and your budgets will not be exceeded. At QPS, we measure our success by your success.

Discovery Lab - Innovation

Our experienced molecular biology and immuno-biomarker scientists can confidently perform the biochemistry of your design, such as a proof-of-concept study originating from your lab or a collaborative effort between you and QPS. In one example, QPS helped a client to generate a toxicity model to screen candidate compounds based on the feedback from the clinical safety data: compounds were incubated with PBMC and the culture media was measured for cytokine levels which had been found to be associated with the side effect observed in the clinical study. Another good example is the big number of new oncology genotyping assays (KRAS, BRAF, PI3KCA) that are validated to support your clinical oncology programs.

The QPS teams in USA, Netherlands, and Taiwan will work to ensure your study is completed to global standards and procedures. Proper optimization and validation of assays are critical steps to your biomarker program. Proper validation includes an assessment of assay sensitivity, specificity and precision. Additional criteria such as accuracy, LLOQ determination, linearity, interferences, normal range evaluation, robustness and other parameters apply for quantitative tests or as appropriate. A method validation report is available upon request.

Find out how to achieve your next development milestone ahead of time.



Biomarker Menu:

- »» Adrenal/Pituitary Disorders
- »» Allergy
- »» Alzheimer's Disease
- »» Anemia
- »» Autoimmune Disease
- »» Bone Disease/Metabolism
- »» Cardiac Markers
- »» Cell Response
- »» Diabetes / Lipid Metabolism / Carbohydrate Metabolism
- »» Gastrointestinal
- »» Hemostasis/Angiogenesis
- »» Infectious Disease
- »» Inflammation / Immune Status / Cell Response
- »» Oncology (Tumor / Neoplasia Markers)
- »» Phenotypic Markers of Drug Metabolism
- »» Renal Toxicity and Function
- »» Reproductive Endocrinology
- »» Thyroid Function

Pharmacogenomics (PGx):

- »» Nucleic Acids Isolation (DNA & RNA) and Banking
- »» Genotyping (SNPs, Insertions, Deletions, Copy Numbers)
- »» CYP450 Genotyping Assays (CYP2B6, CYP3A4, CYP3A5, CYP2C9, CYP2C19, CYP2D6 genotyping panels)
- »» Genotyping Assays for Other Drug Metabolizing Enzymes (NAT1, NAT2, UGT1A1, CDA)
- »» Genotyping Assays for Transporters (ABCG2, SLCO1B1)
- »» Genotyping Assays for Oncology (BRAF, KRAS, PIK3CA)
- »» Genotyping Assays for Alzheimer's Disease (ApoE, PPP3R1)
- »» Genotyping Assays for Warfarin Therapy (CYP2C9*2, CYP2C9*3, and VKORC1 (-1639 G>A))
- »» CpG Methylation Quant
- »» Gene Expression Profiling in various matrices (qRT-PCR)

Immunogenicity Testing:

- »» Anti-Drug-Antibodies (Screening, Confirmation, and Titering)
- »» Antibody Generation
- »» Critical Reagent Labeling
- »» Cell Based Neutralizing Antibody (NAb) Assays
- »» Cell Banking and Maintenance
- »» Technology Transfer
- »» Custom Method Development and Optimization

Neutralizing Antibody (Nab) Assays:

- »» ELISA
- »» Cell-Based Functional Assays, e.g. cell viability assay
- »» Other Functional Assays, e.g. activity assay
- »» Receptor Binding Assays

Novel Biomarker Assay Development:

- »» Various Technology Platforms (ELISA, BioPlex™, Immulite™, MSD ECL, Gyrolab™)
- »» Cell Based Assays
- »» Multiplexing Genetic Markers (CYP450 TaqMan or Affymetrix DMET genechips)
- »» Pharmacodynamic (PD) Assays
- »» On-Site Cell Stimulation and Biomarker Analysis
- »» Fit-For-Purpose Biomarker Assay Development and Validation (various matrices)
- »» Protocol Design

Analytical Platforms:

- »» ELISA
- »» Roche Modular P™
- »» Siemens Immulite™
- »» Bioplex™
- »» Luminex™
- »» Meso Scale Discovery (MSD™) ECL Platform (SECTOR™ PR100, Imager 2400, and Imager 6000)
- »» Gyrolab™
- »» RIA
- »» Radioligand Binding Assay (SPA)
- »» Pyrosequencing Technology Platform
- »» Affymetrix GeneChip Microarray System
- »» TaqMan Real-Time PCR System
- »» Gradient Gel Electrophoresis (GGE)
- »» HPLC/UHPLC
- »» LC - MS/MS
- »» Ultracentrifugation
- »» Western Blot Analysis

Regulatory Status:

- »» CLIA certified
- »» GLP Compliant



Time is of essence so contact one of the following members of the QPS Business Development Team today and find out what QPS can do for you!

QPS-TLM >

Contact: LingSing K. Chen, Ph.D.
 VP and Head of Translational Medicine
 ☎ +302-453-5904
 ✉ lingsing.chen@qps-usa.com

From left to Right: Level 1: Jerry Gromelski, Irma Scheepstra, Level 2: Jeff Moran, Edwin van Vulpen, Livia Legg, Andrew Nehls, Lily Rosa, Jelle Hempenius, Marina Abanto, Mary Ann Gagnon, Brendon Bourg, Level 3: Jim Cunningham, Wendy Nelson

Europe >

Bioanalysis, DMPK & Toxicology	Early Stage Clinical
Contact: Jelle Hempenius ☎ +31 50 304 8000 ✉ jelle.hempenius@qps.com	Contact: Edwin van Vulpen ☎ +31 50 304 8000 ✉ edwin.van.vulpen@qps.com
Late Stage Clinical	
Contact: Irma Scheepstra ☎ +31 50 304 8000 ✉ irma.scheepstra@qps.com	

HQ BD Office >

USA

Contact: Lily Rosa
 ☎ +1 512 350 2827
 ✉ lily.rosa@qps-usa.com

Contact: Mary Ann Gagnon
 ☎ +302-369-5137
 ✉ maryann.gagnon@qps-usa.com

North America >

Bioanalysis, DMPK & Toxicology	Early & Late Stage Clinical
Northeast: Wendy Nelson ☎ +1 508 543 0228 ✉ wendy.nelson@qps-usa.com	East Coast: Andrew Nehls ☎ +1 402 895 2022 ✉ andrew.nehls@qps-usa.com
Mid Atlantic: Jerry Gromelski ☎ +1 570 451 3015 ✉ jerry.gromelski@qps-usa.com	Central: Jim Cunningham ☎ +1 402 541 6041 ✉ jim.cunningham@qps-usa.com
Southeast: Marina Abanto ☎ +1 513 232 4772 ✉ marina.abanto@qps-usa.com	West Coast: Jeff Moran ☎ +1 302 690 2163 ✉ jeff.moran@qps-usa.com
Central: Jim Cunningham ☎ +1 402 541 6041 ✉ jim.cunningham@qps-usa.com	
West Coast: Jeff Moran ☎ +1 302 690 2163 ✉ jeff.moran@qps-usa.com	

Asia >

Taiwan

Contact: Alex Chang
 ☎ +886 2 2655 7555
 ✉ alex.chang@qps-taiwan.com.tw

India

Contact: Manish Kalwani
 ☎ +91 40 2377 0873 74
 ✉ manish@bioserve.co.in

Japan

Contact: Alex Chang
 ☎ +886 2 2655 7555
 ✉ alex.chang@qps-taiwan.com.tw

Other Asian Countries

Contact: Alex Chang
 ☎ +886 2 2655 7555
 ✉ alex.chang@qps-taiwan.com.tw